Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab in Relapsed/Refractory Small Cell Lung Cancer (DeLLphi-301)
NCT05060016Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Dec 2021
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 18
01
Overview
A Phase 2 trial of tarlatamab in small cell lung cancer (SCLC), sponsored by Amgen. Started Dec 2021; status: active, not recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05060016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05060016.